CDC/ACIP [to 6 May 2017]

CDC/ACIP [to 6 May 2017]

Press Release
Friday, May 05, 2017
CDC updates guidance on interpretation of Zika testing results for pregnant women
Recommendations focus on women who live in or frequently travel to areas with a CDC Zika travel notice
The Centers for Disease Control and Prevention (CDC) today issued a Health Alert Notice with updated guidance for healthcare professionals to interpret Zika test results for women who live in, or frequently travel (daily or weekly) to areas with a CDC Zika travel notice.

This change is being made because CDC’s Zika testing guidance for pregnant women relies, in part, on a test [Zika virus Immunoglobulin M (IgM) ELISA] to detect Zika antibodies or proteins that the body makes to fight Zika infections. New data suggest that Zika virus infection, similar to some other flavivirus infections, may result in Zika antibodies staying in the body for months after infection for some individuals. As a result, results of these tests may not be able to determine whether women were infected before or after they became pregnant.

Specifically, CDC recommends the following guidance for healthcare professionals evaluating women without symptoms who had potential Zika exposure—particularly women who live in or frequently travel (daily or weekly) to areas with CDC Zika travel notices. Use of these tests may be helpful, but may not always be conclusive, in distinguishing how recent the infection is.

:: Screen pregnant women for risk of Zika exposure and symptoms of Zika. Test pregnant women promptly, using nucleic acid testing (NAT), if they develop symptoms at any point during pregnancy or if their sexual partner tests positive for Zika virus infection;
:: Consider NAT testing at least once during each trimester of pregnancy to detect evidence of Zika virus, unless a previous test has been positive;
:: Consider testing specimens obtained during amniocentesis to detect evidence of Zika virus if amniocentesis is performed for other reasons;
:: Counsel all pregnant women each trimester about the limitations of Zika testing.’’…

MMWR News Synopsis for May 4, 2017
Progress Toward Measles Elimination — African Region, 2013–2016
CDC Media Relations (404) 639-3286
To eliminate measles by 2020, countries in the region and partners need to 1) achieve ≥95% two-dose measles vaccine coverage through improved immunization services, including introducing a second vaccine dose of measles into routine immunization schedules; 2) improve vaccine campaign quality by preparing 12–15 months in advance, and using related preparation and assessment tools; 3) fully perform necessary disease surveillance for elimination purposes; 4) conduct annual district-level risk assessments; and 5) establish commissions to verify measles elimination. Countries in the World Health Organization African Region show progress and setbacks toward a regional goal of measles elimination by 2020. The number of new cases annually in the region has decreased by 63% from 2013 to 2016. However, not enough children are receiving the recommended two doses of vaccine to provide full protection against measles. The majority of children in the region not being fully protected against measles reside in four countries: Nigeria, Ethiopia, the Democratic Republic of the Congo, and Angola; these countries also account for the majority of the region’s measles cases each year. Only half of all African Region countries have introduced a second vaccine dose against measles. For the region to eliminate measles by 2020, efforts are needed for countries to achieve ≥95% two-dose coverage.